The landscape of Chimeric Antigen Receptor T-cell (CAR-T) therapies is witnessing rapid evolution as emerging companies introduce innovative solutions to overcome existing challenges. These therapies, which involve genetically engineering a patient’s T cells to target cancer cells, have shown i
Advancements in cancer treatments have always been a focal point in medical research. Mustang Bio, Inc. (Nasdaq: MBIO) has recently made significant strides in the battle against Waldenstrom macroglobulinemia (WM), a rare type of blood cancer. Their latest clinical trial results for MB-106, a
In a bold move that underscores its commitment to oncology and global expansion, Japan-based Ono Pharmaceutical Co., Ltd. has finalized its acquisition of Deciphera Pharmaceuticals Inc., a U.S. biopharmaceutical firm specializing in cancer treatments. The transaction was settled with the purchase
Recent actions by U.S. House lawmakers have cast a spotlight on GenScript, a Chinese Contract Development and Manufacturing Organization (CDMO), and its cell therapy division, Legend Biotech, amidst concerns of potential Chinese Communist Party (CCP) influence within the American biotech realm.
As the battle against cancer continues, one particular area showing remarkable strides is colorectal cancer research and treatment. With over 195 key players in the industry, a testament to the competitive yet collaborative nature of the field, advancements are moving at an incredible pace. From
The biotech industry is at a crossroads, grappling with the challenges and expectations set by cell therapies. Oncology-focused treatments that once held great promise are now facing a reality check, prompting many companies to reevaluate their focus on autoimmune diseases. As expectations align
